GSK and Shenzhen Neptunus in £52 million flu vaccine joint venture
This article was originally published in Scrip
Executive Summary
GlaxoSmithKline and Shenzhen Neptunus of China are to invest £52 million in a new joint venture to develop and manufacture influenza vaccines in China. GSK has an established business in China, but the alliance represents its first move into the Chinese influenza vaccines market.